The Next Frontier of Focus

The life sciences industry is divided – not by therapeutic modality, but by time horizon. While biotech start-ups often gain attention for breakthroughs in acute conditions like infections or neurological diseases, pharmaceutical giants are building their future around chronic disease. In the United States, 6 in 10 adults live with at least one chronic illness, contributing to an estimated $4.5 trillion in annual healthcare costs.¹ This is not a passing trend but a structural shift grounded in long-term revenue models, the growing global burden of chronic illness, and the alignment between digital technologies and long-duration treatment pathways. 

Why Do Chronic Diseases Dominate Pharma Strategy?

The pharmaceutical industry has structurally shifted its priorities toward chronic conditions. Why?

• Revenue Stability: Long-term treatments generate recurring revenue over years, not weeks.
  
• Multi-Indication Potential: Many chronic diseases co-occur (e.g., obesity, heart failure, kidney disease), enabling broader applicability of platform drugs.
  
• Technology Alignment: AI, gene therapy, and precision medicine are especially well-suited for chronic disease targeting, helping justify high R&D investments.²
  
• Blockbuster Potential: In 2024, 9 of the 10 top-selling drugs globally were for chronic diseases such as cancer, diabetes, and autoimmune conditions.³
  

Even newer therapeutic platforms like mRNA and gene therapy – initially developed for acute infectious diseases like COVID-19 – are pivoting toward chronic indications, including metabolic and cardiovascular disorders.⁴

Investors Are Doubling Down on Chronic

Venture capital flows are mirroring pharma’s long-term priorities. In Q1 2025, oncology remained the leading therapeutic area with 76 deals backed by 217 investors, which reflects the sector’s ongoing strategic importance.⁵ Meanwhile, chronic conditions like autoimmune and central nervous system (CNS) disorders are attracting growing attention from specialized VCs such as Vie Ventures and Lightstone, which are now focusing almost exclusively on these long-duration, high-burden indications.⁶

Digital health is also reinforcing the trend: nearly 62% of all digital health VC funding in H1 2025 went toward chronic disease management tools, including AI-driven platforms for diagnostics, remote monitoring, and personalized treatment planning.⁷

By contrast, companies focused on acute and infectious diseases face continued funding challenges, with a few exceptions tied to pandemic preparedness or niche use cases.⁸

BD Implications: Where the Dealmaking Energy Flows

For business development leaders, these trends have clear implications:

• Chronic care platforms have greater long-term BD value due to pipeline longevity and multi-indication potential.
  
• Acute innovation must be highly differentiated: through speed, platform potential, or emergency relevance, to attract strategic buyers.
  
• Digital health and AI integrations targeting chronic pathways are gaining traction in both partnerships and investment circles.⁷
  

Ultimately, chronic care equals commercial longevity. That’s where BD momentum is flowing.

Final Insight

The distinction between acute and chronic conditions is more than clinical – it’s strategic. As pharma doubles down on personalized, tech-enabled, long-duration care, chronic disease is not just the therapeutic focus of the future – it’s the structural backbone of the industry’s long-term growth model.

How Liberi Group Can Help

At Liberi Group, we help biotech companies and investors bridge the science-to-market gap.

Whether you are looking to:

• Position your platform for partnership,
  
• Craft a compelling pitch for investors, or
  
• Evaluate strategic fit across therapeutic areas and indications,
  
• we can support your business development journey. Get in touch to explore how we can help align your science with the right market, strategy, and partners.